Apollo AyurVAID Launches India's First ‘Tested Safe' Ayurveda Products
Launches 50 SKUs across classical Ayurveda formulations, OTC products, and medical foods
Targets nationwide reach and Rs. 500 crores in Products revenue in the next 5 years
Apollo AyurVAID, India's leading NABH-accredited, precision Ayurveda hospital network, announces its strategic foray into the Ayurveda product segment, marking a significant expansion beyond clinical care. The new portfolio spans classical formulations, OTC products, and medical foods, crafted to meet the growing demand for safe, clinically validated Ayurveda products in India's ~ Rs. 60,000 crore market growing at over 16% annually.
Apollo AyurVAID launches India's first 'Tested Safe' Ayurveda products
In an industry first, Apollo AyurVAID's product range features clinically proven formulations that are certified safe by NABL-accredited laboratories with respect to presence of heavy metals, aflatoxins, microbial content, etc., as applicable for different product types. Apollo AyurVAID's products set the highest, proof-backed, safety benchmark in the Ayurveda product market with the consumer able to verify test results (QR code on packaging) for each and every product they consume. This reinforces Apollo AyurVAID's resolve to offer safer, standardised, and effective Ayurveda products that the market can implicitly trust.
Dr. Preetha Reddy, Executive Vice Chairperson, Apollo Hospitals and Chairperson, Apollo AyurVAID said, 'Apollo AyurVAID's foray into tested-safe Ayurveda products marks a pivotal step in redefining standards of safety, transparency, and efficacy in traditional medicine. This expansion builds on a strong foundation of clinical excellence and reflects a deep commitment to evidence-based, precision Ayurveda. By integrating innovation with time-honoured wisdom, Apollo AyurVAID is well on its way to shaping the future of integrative medicine in India and beyond.'
Commenting on this strategic initiative, Mr. Rajiv Vasudevan, Founder, MD, and CEO, Apollo AyurVAID said, 'With two decades of clinical excellence behind us, we are extending our understanding of precision Ayurveda and credibility into a high-potential consumer space. This new vertical not only complements our inpatient-outpatient care model but also opens scalable revenue opportunities and reinforces our vision of mainstreaming evidence-based Ayurveda services and products by making it accessible globally. We anticipate this portfolio will be a key growth driver, with a revenue aspiration of Rs. 500 crores in the next 5 years.'
The Ayurveda products division is being developed as a business unit of Apollo AyurVAID, while staying firmly rooted in Apollo AyurVAID's commitment to precision Ayurveda for personalised, safe, clinical-outcomes-driven health care.. While classical formulations will be available through prescription, the OTC and medical foods lines will be available through a wide network of retail and digital platforms. The OTC range features innovative medicine formats such as creams, transdermal pads, essential extracts, etc., for special customer segments (women, child, elder, etc.) and applications (pain, sleep, stress, skin etc.), with highest medical content assuring best-in-class product performance. Apollo AyurVAID has recently partnered with integrated systems biology platform company, Avesthagen Limited, to co-develop and offer scientifically validated, botanical-actives based dietary supplements that are sugar-free, artificial colour & flavours free; this shall be followed with an Ayurveda based medical foods range for specific clinical indications.
The classical and OTC product range are branded 'AyurVAID' while the dietary supplements are branded 'AvestaAyurVAID'. This strategic expansion reinforces Apollo AyurVAID's vision of building a credible, science-led ecosystem for precision Ayurveda and evolving into a full-spectrum Ayurveda company.
'As we enter the Ayurveda products space, our broader vision is to take the Apollo AyurVAID brand across the length and breadth of India.In the current fiscal we plan to expand our hospital network in an asset-light manner by adding 9 new points of presence, scaling our bed capacity to 350, aiming to treat over 50,000 patients. With a CAGR of 75% over the last 2-3 years, we are on track to surpass the annualised Rs. 100 crore revenue mark by mid next year – an unprecedented milestone in Ayurveda's services sector. This is just the beginning of our journey to take Apollo AyurVAID, India's most credible, precision Ayurveda care, to every corner of the country and across the globe,' added Mr. Rajiv Vasudevan.
Distribution for the new portfolio will follow a multi-tier strategy, with availability across Apollo AyurVAID's hospitals and clinics, the company's website, Apollo Pharmacies, Apollo 24|7 and leading e-commerce platforms. This integrated channel approach is designed to enable access and reach to a wider audience.
About Apollo AyurVAID
Apollo AyurVAID (www.ayurvaid.com) is India's leading chain of protocol-driven Ayurveda hospitals and integrative care centres, delivering evidence-based, 'Precision Ayurveda' for chronic disease reversal, management, and sustained wellbeing. Since its inception in 2005, Apollo AyurVAID has been committed to transforming Ayurveda into a mainstream, protocols, documentation and clinical-outcomes driven system of medicine with hospitals and clinics spread across Bengaluru, Chennai, New Delhi, Kochi, Almora and Hyderabad.
Founded in 2005 and part of the Apollo group since 2022, Apollo AyurVAID has emerged as a pivotal force in formalising Ayurveda-led integrative care, developing a unique care model that combines traditional Ayurvedic wisdom with modern clinical rigour. The chain of hospitals has demonstrated an impactful model of integrative care across specialties including neurology, oncology, nephrology, obstetrics and gynaecology, and metabolic disorders, with a focus on adjuvant therapy, palliative care, rehabilitation, and primary intervention. Apollo AyurVAID's unique 'Whole Person Care' approach considers the whole person to treat multimorbidity, not just at symptom level but at root-cause level, and supports health across the entire life cycle, from prevention and treatment to rehabilitation, survivorship and wellbeing.
The first and only Ayurveda institution to receive the prestigious QCI DL Shah National Quality Award (2012), Apollo AyurVAID is also India's first NABH-accredited Ayurveda hospital (2010). It is also the first to gain NABH accreditation for Ayurveda para surgery (2013) and five hospitals in its countrywide network are NABH-accredited. In 2023, it became the first and only QAI-accredited Ayurveda and integrative medicine based Transition Care Centre in India.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
News18
an hour ago
- News18
ICMR says Indians taking too much salt, launches study to address issue
New Delhi, Jul 13 (PTI) Excessive salt consumption is fuelling a silent epidemic in India with people at increased risk of hypertension, stroke, heart disease, and kidney disorders, according to scientists from ICMR's National Institute of Epidemiology. The scientists have initiated a community-led salt reduction study to address the issue and are focusing on low sodium salt substitutes. While the World Health Organisation (WHO) recommends less than 5 grams of salt per person per day, studies show that urban Indians consume around 9.2 grams/day, and even in rural areas it is around 5.6 grams/day – both higher than recommended. One promising tool in this effort is low-sodium salt substitutes — �blends where part of the sodium chloride is replaced with potassium or magnesium salts, Dr Sharan Murali, a senior scientist at National Institute of Epidemiology (NIE) and principal investigator of the study, said. 'Lesser sodium consumption helps reduce blood pressure and improves overall heart health, making low-sodium alternatives a meaningful switch, especially for those with hypertension," Dr Murali stated. 'Just switching to low-sodium salt can lower blood pressure by 7/4 mmHg on average'�a small change with a big impact," Dr Murali said. To tackle the issue of high salt consumption, the NIE has launched a three-year intervention project in Punjab and Telangana, supported by the Indian Council of Medical Research (ICMR). The goal is to evaluate the effectiveness of structured salt reduction counselling, delivered by health workers at Health and Wellness Centres (HWCs), in reducing blood pressure and sodium intake among individuals with hypertension, senior scientist at NIE, Dr Ganesh Kumar, who is also a part of the study, said.. 'We are currently in the first year of the project, focused on baseline assessments and field preparations," Dr Kumar said. 'Counselling materials are not yet finalised; rather, we aim to co-create the intervention package with the community health workers, drawing on their experiences and incorporating their suggestions. It's not just about delivering health education – �it's about listening, understanding, and building together," Dr Murali said. To ensure interventions are grounded in reality, the NIE conducted a market survey across 300 retail outlets in Chennai to assess the availability and pricing of low-sodium salt (LSS). They found that LSS was available in only 28 per cent of retail outlets. It was seen in 52 per cent of supermarkets, but a dismal 4 per cent in small grocery shops. The price of LSS averaged Rs 5.6 per 100g, more than twice the price of normal iodised salt (Rs 2.7 per 100g). These findings highlight a critical supply-demand disconnect, Dr Murali said. 'The lower demand for low sodium salt might be leading to its lower availability – it's a proxy indicator of awareness and access," noted Dr. Murali. To spark a public conversation around salt reduction, the NIE has also recently launched the #PinchForAChange campaign on Twitter and LinkedIn through ICMR-NIE. Using infographics, facts, and simple messages, the campaign aims to raise awareness about hidden salt sources, promote low-sodium alternatives, and empower individuals to make heart-healthy choices. 'If successful, this project could lead to the integration of sustainable dietary counselling models into the existing public health system. It can bridge the gap between knowledge and action, improve health literacy, and ultimately reduce the burden of hypertension-related diseases. 'This is not just about reducing salt. It's about restoring balance in our diets, our systems, and our hearts. Together, one pinch at a time, we can create lasting change," Dr Murali added. PTI PLB DV DV view comments First Published: July 13, 2025, 12:30 IST Disclaimer: Comments reflect users' views, not News18's. Please keep discussions respectful and constructive. Abusive, defamatory, or illegal comments will be removed. News18 may disable any comment at its discretion. By posting, you agree to our Terms of Use and Privacy Policy.
&w=3840&q=100)
Business Standard
an hour ago
- Business Standard
Cipla to enter weight management segment in India: MD & Global CEO Vohra
Drug major Cipla is preparing to foray into the weight management segment in India, its MD and global CEO Umang Vohra has said. The Mumbai-based firm is also strengthening its presence in the central nervous system (CNS) therapeutic area, he stated in his address to shareholders in the company's Annual Report for 2024-25. "Our efforts are rooted in understanding patient needs, reducing stigma, and delivering differentiated therapies for niche is emerging as a priority area for Cipla. With a clear strategic intent, we are preparing to enter the weight management segment in India, aiming to address the rising demand for effective obesity solutions," Vohra stated. Several domestic drug firms are developing drugs for weight loss to capitalise on the growing market for obesity and diabetes management. US drugmaker Eli Lilly & Co has already launched its anti-obesity drug Mounjaro in the country. Danish firm Novo Nordisk has also launched its anti-obesity drug Wegovy, indicated for both long-term chronic weight management and reduction in risk of major adverse cardiovascular events. In the CNS segment, Cipla has successfully in-licensed Sanofi's India CNS product range, including Frisium, a leading brand in the anti-epileptic category, Vohra informed shareholders. "Building on this momentum, we aim to pursue similar in-licensing deals or acquisitions in niche indications of attention deficit hyperactivity disorder (ADHD) and Parkinson's disease," he said. The company is equally committed to addressing the global crisis of antimicrobial resistance (AMR), he added. "Our AMR portfolio is evolving from volume-based to innovation-led, with four novel products in development," Vohra said. He noted that the company's ambition is to be a global, innovation-led, patient-centric healthcare company that creates long-term value through science, empathy, and sustainability. "We will continue to invest in big brands, strategic alliances, digital infrastructure, and next-generation therapies, while remaining rooted in our founding values of care and compassion," Vohra stated. Cipla's consolidated revenue stood at Rs 27,548 crore in FY25. Its consolidated net profit rose to Rs 5,272 crore during the period.
Time of India
2 hours ago
- Time of India
Cipla eyes entry into India's weight management market amid rising demand and global competition
Drug major Cipla is preparing to foray into the weight management segment in India, its MD and global CEO Umang Vohra has said. The Mumbai-based firm is also strengthening its presence in the central nervous system (CNS) therapeutic area, he stated in his address to shareholders in the company's Annual Report for 2024-25. "Our efforts are rooted in understanding patient needs, reducing stigma, and delivering differentiated therapies for niche is emerging as a priority area for Cipla. With a clear strategic intent, we are preparing to enter the weight management segment in India, aiming to address the rising demand for effective obesity solutions," Vohra stated. Several domestic drug firms are developing drugs for weight loss to capitalise on the growing market for obesity and diabetes management. US drugmaker Eli Lilly & Co has already launched its anti-obesity drug Mounjaro in the country. Live Events Danish firm Novo Nordisk has also launched its anti-obesity drug Wegovy, indicated for both long-term chronic weight management and reduction in risk of major adverse cardiovascular events. In the CNS segment, Cipla has successfully in-licensed Sanofi's India CNS product range, including Frisium, a leading brand in the anti-epileptic category, Vohra informed shareholders. "Building on this momentum, we aim to pursue similar in-licensing deals or acquisitions in niche indications of attention deficit hyperactivity disorder (ADHD) and Parkinson's disease," he said. The company is equally committed to addressing the global crisis of antimicrobial resistance (AMR), he added. "Our AMR portfolio is evolving from volume-based to innovation-led, with four novel products in development," Vohra said. He noted that the company's ambition is to be a global, innovation-led, patient-centric healthcare company that creates long-term value through science, empathy, and sustainability. "We will continue to invest in big brands, strategic alliances, digital infrastructure, and next-generation therapies, while remaining rooted in our founding values of care and compassion," Vohra stated. Cipla's consolidated revenue stood at Rs 27,548 crore in FY25. Its consolidated net profit rose to Rs 5,272 crore during the period.
